167 related articles for article (PubMed ID: 37120335)
21. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
Liedberg F; Kollberg P; Allerbo M; Baseckas G; Brändstedt J; Gudjonsson S; Hagberg O; Håkansson U; Jerlström T; Löfgren A; Patschan O; Sörenby A; Bläckberg M
Eur Urol; 2020 Nov; 78(5):e186-e187. PubMed ID: 32950295
[No Abstract] [Full Text] [Related]
22. Reply to Giovanni Lughezzani, Paolo Casale, and Laura Evangelista's Letter to the Editor re: Giuseppe Basile, Giuseppe Fallara, Paolo Verri, et al. The Role of
Basile G; Gallioli A; Chiti A; Capitanio U; Breda A
Eur Urol; 2024 Mar; 85(3):e77-e78. PubMed ID: 38092616
[No Abstract] [Full Text] [Related]
23. Reply to Shun-Fa Hung, Shyi-Chun Yii, and Shiu-Dong Chung's Letter to the Editor re: Zhiwen Chen, Peng He, Xiaozhou Zhou, et al. Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder Suspension with Round Ligaments in Women with Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.012.
He P; Zhou X; Chen Z
Eur Urol; 2022 May; 81(5):e119. PubMed ID: 35125227
[No Abstract] [Full Text] [Related]
24. Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
Takemura K; Yuasa T; Choueiri TK; Heng DYC
Eur Urol; 2024 Mar; ():. PubMed ID: 38531704
[No Abstract] [Full Text] [Related]
25. Reply to Giancarlo Marra, Marco Oderda, Paolo Gontero, and Lorenzo Richiardi's Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015.
Hu JC; Allaf ME; Vickers AJ; Schaeffer EM
Eur Urol; 2024 Apr; ():. PubMed ID: 38599991
[No Abstract] [Full Text] [Related]
26. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
Trock BJ; Karnes RJ
Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
[No Abstract] [Full Text] [Related]
27. Reply to Eoin Dinneen, Jon Oxley, and Greg Shaw's Letter to the Editor re: Bernardo Rocco, Luca Sarchi, Simone Assumma, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.021.
Rocco B; Cimadamore A; Sighinolfi MC; Assumma S; Montironi R
Eur Urol; 2021 Nov; 80(5):e122-e123. PubMed ID: 34483006
[No Abstract] [Full Text] [Related]
28. Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016.
Garcia-Ruiz A; Macarro C; Mateo J; Perez-Lopez R
Eur Urol; 2024 May; ():. PubMed ID: 38760292
[No Abstract] [Full Text] [Related]
29. Reply to Can Lu and Xiao Guan's Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022.
Babjuk M
Eur Urol; 2020 Aug; 78(2):e73-e74. PubMed ID: 32389446
[No Abstract] [Full Text] [Related]
30. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Loehr A; Chowdhury S; Abida W
Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
[No Abstract] [Full Text] [Related]
31. Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolás Badillo's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009.
Ilie G; David Harold Rutledge R
Eur Urol; 2023 Jul; 84(1):e26-e27. PubMed ID: 37127468
[No Abstract] [Full Text] [Related]
32. Reply to Kenta Ushida, Miho Shimizu, and Ryo Momosaki's Letter to the Editor re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.05.015. Strategies for Effective Prehabilitation in Urologic Cancer.
Briggs LG; Parke S; Bain PA; Psutka SP
Eur Urol; 2021 Dec; 80(6):e141-e142. PubMed ID: 34565629
[No Abstract] [Full Text] [Related]
33. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Wilkinson S; Ye H; Lis RT; Sowalsky AG
Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
[No Abstract] [Full Text] [Related]
34. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Chesnut GT; Vertosick EA; Ehdaie B
Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
[No Abstract] [Full Text] [Related]
35. Reply to Giancarlo Marra, Armando Stabile, Paolo Gontero, Francesco Montorsi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019: A Storm in a Teacup.
Meissner VH; Gschwend JE; Heck MM
Eur Urol; 2022 May; 81(5):e117. PubMed ID: 35131117
[No Abstract] [Full Text] [Related]
36. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Tan WS; Kelly JD;
Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
[No Abstract] [Full Text] [Related]
37. Reply to Kirti Singh, Swarnendu Mandal, Manoj Kumar Das, Prasant Nayak, and Sambit Tripathy's Letter to the Editor re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021.
Che Y; Hiester A; Albers P
Eur Urol; 2023 Jun; 83(6):e157. PubMed ID: 36870796
[No Abstract] [Full Text] [Related]
38. Reply to Jinna Yao, Henry C.C. Pleass, and Howard M.H. Lau's Letter to the Editor re: Andrea Gallioli, Angelo Territo, Romain Boissier, et al. Learning Curve in Robot-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.008.
Gallioli A; Territo A; Breda A
Eur Urol; 2020 Jun; 77(6):e166-e167. PubMed ID: 32291108
[No Abstract] [Full Text] [Related]
39. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB; Drake CG; Fizazi K
Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
[No Abstract] [Full Text] [Related]
40. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
Tomlins SA; Groskopf J; Chinnaiyan AM
Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
